Plus Therapeutics Expands CNSide Assay Platform to State of California
PLUS THERAPEUTICS, Inc. (PSTV)
Company Research
Source: GlobeNewswire
HOUSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces that it has been granted lab licenses to provide the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) laboratory developed test (LDT) in California, Rhode Island and Maryland. “CNSide Diagnostics is now licensed to provide our proprietary testing service in 48 of 50 U.S. states and obtaining state licensure is a key enabler of our plan to bring the benefits of CNSide CSF testing to the broadest possible set of patients with CNS cancers,” said Russ Bradley, CNSide Diagnostics, LLC President and General Manager. “We remain focused on executing on U.S. market access and launch strategy and look forward to continued expansion of coverage across payo
Show less
Read more
Impact Snapshot
Event Time:
PSTV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PSTV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PSTV alerts
High impacting PLUS THERAPEUTICS, Inc. news events
Weekly update
A roundup of the hottest topics
PSTV
News
- Plus Therapeutics (NASDAQ:PSTV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.MarketBeat
- Plus Therapeutics Expands CNSide Assay Platform to State of California [Yahoo! Finance]Yahoo! Finance
- Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement GrantsGlobeNewswire
- Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual MeetingGlobeNewswire
- Plus Therapeutics (NASDAQ:PSTV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.MarketBeat
PSTV
Earnings
- 8/14/25 - Beat
PSTV
Sec Filings
- 11/17/25 - Form 8-K
- 11/5/25 - Form 4
- 10/30/25 - Form 10-Q
- PSTV's page on the SEC website